At 8.4% CAGR, the Asia Pacific Deep Brain Simulation Market is Projected to be worth US$ 188.04 million by 2030, says Business Market Insights

According to Business Market Insights research, the Asia Pacific deep brain simulation market was valued at US$ 98.35 million in 2022 and is expected to reach US$ 188.04 million by 2030, registering a CAGR of 8.4% from 2022 to 2030. Increasing demand for minimally invasive surgery and technological advancements and approvals in deep brain stimulation are the critical factors attributed to the Asia Pacific deep brain simulation market expansion.

Deep brain stimulation is a minimally invasive targeted surgery used to treat movement disorders in dystonia, Parkinson's disease, and essential tremor. Minimally invasive surgeries (MIS) offer several advantages over traditional surgical techniques. MIS minimizes trauma to the body, reduces postoperative pain, increases recovery speed, and improves outcomes. Robotic procedures represent the latest evolution in minimally invasive procedures, providing surgeons with precision equipment that uses the same small incisions used in traditional laparoscopy. MIS leads to less blood loss, less analgesic use, and shorter postoperative hospital stay than open surgery. In addition, minimally invasive surgery indicates a higher accuracy rate than traditional surgical methods. Also, these procedures require tiny incisions large enough to insert thin tubes and cameras. These benefits of MIS are increasing inpatients and have encouraged older patients who face high operative morbidity and mortality to seek surgery. Thus, the rising demand for minimally invasive surgeries due to their advantages bolsters the deep brain stimulation (DBS) market growth.  

On the contrary, side effects associated with deep brain stimulation hurdles the growth of Asia Pacific deep brain simulation market.

Based on product, the Asia Pacific deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. The dual channel deep brain stimulator segment held 48.8% share of Asia Pacific deep brain simulation market in 2023, amassing US$ 47.97 million. It is projected to garner US$ 98.65 million by 2030 to expand at 9.4% CAGR during 2022–2030.

Based on application, the Asia Pacific deep brain simulation market is segmented into Parkinson’s disease, tremor, dystonia, epilepsy, Alzheimer’s disease, and others. The Parkinson’s disease segment held 68.2% share of Asia Pacific deep brain simulation market in 2023, amassing US$ 77.33 million. It is projected to garner US$ 147.16 million by 2030 to expand at 8.4% CAGR during 2022–2030.

Based on end user, the Asia Pacific deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. The hospitals segment held 59.7% share of Asia Pacific deep brain simulation market in 2022, amassing US$ 58.74 million. It is projected to garner US$ 117.45 million by 2030 to expand at 9.0% CAGR during 2022–2030.  

Based on country, the Asia Pacific deep brain simulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 40.3% share of Asia Pacific deep brain simulation market in 2022. It was assessed at US$ 39.61 million in 2022 and is likely to hit US$ 82.73 million by 2030, exhibiting a CAGR of 9.6% during 2022–2030.  

Key players operating in the Asia Pacific deep brain simulation market report Abbott Laboratories, Beijing PINS Medical Co Ltd, Boston Scientific Corp, Medtronic Plc, and SceneRay Co Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com